Term
| two classes of asthma treatment |
|
Definition
| bronchodilators- relieve acute symptoms , anti inflammatory agets - used to control/prvent symtpoms |
|
|
Term
| bronchodilators moa and types |
|
Definition
| increased cAMP0 either via b-agonists, or pde inhibitors (which normally break down camp). muscarinic ad adenosine antagonists blocks broncdhoconstrictoin. |
|
|
Term
| b-agonists actions in asthma |
|
Definition
| relax bronchial smc, inhbiit the realeas eof bornhoonstrictors from mast cells. inhibit microvascular leake andi icnreasemucocilliary trasport |
|
|
Term
| nonselective b agonists actions |
|
Definition
| stimulates b2 receptors- bronchodilation, and b1 receptors- cardio side effects. epinephrine. NOT FOR CHRONIC USE, |
|
|
Term
|
Definition
| nonsleective b agonists, muchlower potency than epinephrile but orally active |
|
|
Term
|
Definition
| nonselective b a gonist, very poten t but shrot acting bronchodilator. mosly use dto emergencies |
|
|
Term
| b2 selective adrenorecpetor agoists |
|
Definition
| both short actinga and long acting. Last logner than nonselective agaonsits. used for relie of acute asthma smtpoms adn bronchospasm |
|
|
Term
|
Definition
| shortactingselective b2 agonist, all b2 agonists end in-ols, |
|
|
Term
|
Definition
|
|
Term
|
Definition
| used frequqently i chidlren, ho can controll meter dose, or patient with very severe asthma that aerosol iritates them. adverse effects include: skeletal muscle tremr, nervousnes,s ocassional weakness |
|
|
Term
| subcu therapy for b 2 agonist used when? |
|
Definition
| emergency treatment where aerosol not usable. teru ullatiilien is the only one |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| long acting b2 agonist duration of action |
|
Definition
| 12 hours or more, slow onset, so cant be used for acute exacerbation, |
|
|
Term
| use of long acting b selective |
|
Definition
| with inhaled corticosteroids, not used alone because no antiinflammatory effect |
|
|
Term
|
Definition
| a potent selective b2 receptor agonist that is long acting AND works acutely. available as nebulizer |
|
|
Term
|
Definition
|
|
Term
|
Definition
| inhibit PDE- increasing camp, also inhibit adenosine- which inhibits bronchoconstriction |
|
|
Term
| methylxanthien drug utility |
|
Definition
| relaxatio of airway smc major hteapurtic action in asthma. Cn alo improv contrcitly of isolated skeletal muscle, reverse fatigue of daiaphragm in patietn with copd. use fo racute asthma |
|
|
Term
| adverse effect sof methylxanthi e drugs |
|
Definition
| cns effects, cardio effects, gi effects, |
|
|
Term
| methylxanthine method of admin |
|
Definition
|
|
Term
| treatment with theophylline gudeliens |
|
Definition
| constnat monitoing of plasma levels. needs to be bewee 5-20 mg/L |
|
|
Term
|
Definition
| antiparasympathetic , avoid cbronchoconstriction |
|
|
Term
|
Definition
| muscarinic antagonist, however adverse effects may occur including cardiac effects |
|
|
Term
|
Definition
| mucarinic recpeotr antagonist , |
|
|
Term
| ipratropium bromide properites |
|
Definition
| qurternary ammonium , so delivered inhaled, without entering cns or beinga bsorbed ssytemtically. used in combo with b2 agonist . effective in COPD |
|
|
Term
| ipratropium bromide properites |
|
Definition
| qurternary ammonium , so delivered inhaled, without entering cns or beinga bsorbed ssytemtically. used in combo with b2 agonist . effective in COPD |
|
|
Term
|
Definition
| logner acting version ofipratropium |
|
|
Term
|
Definition
DO NOT relax smc. inhibit mucousal inflammation in asthamtic airways, antiinflammtoryenffect by reducing cyotkiens/chemokines. eicosanoid synth, inhib acumulation of phils ad luekotrienes.
reduce frequency of asthma excaerbations, potentiates teh eects of b agonists when administered chronically |
|
|
Term
| adminitratiomethod corticosteroids asthma |
|
Definition
| almost always given aerosol to reduce adverse effects , unless emergencythen given orally |
|
|
Term
|
Definition
|
|
Term
| corticosteroid adverse effectsasthma |
|
Definition
| oropharyngeal candidiasis, grwoth retardation possile in children |
|
|
Term
| cromoln sodium , nedocormil sodium moa |
|
Definition
| used prophylactically only. delayed cholride channel activvation , inhibitign celluar activation. |
|
|
Term
|
Definition
| pretreatment, blocks bronchoconcstriction, must be taken at least an hour bbefore exposed, may prevent trigger from working. may reduce need for bronchodilation. can be usedf or rhinonjunctivis. |
|
|
Term
|
Definition
| antiluekotriene. bock 5lipoxeygenase, prventing luekotriene syntehsis |
|
|
Term
|
Definition
| ltd4 receptor antatogonist |
|
|
Term
|
Definition
| ltd4 receptor antatogonist |
|
|
Term
|
Definition
| block airway reponse, reduce bronchial reactivity and iarway inflammation so have less exacerbations. However not everyone respodns to it |
|
|
Term
| antiluekotriene administration |
|
Definition
| can be given orally , if inhalation is not an option |
|
|
Term
|
Definition
|
|
Term
|
Definition
| temporary hepatitis when on drug. Alot of drug-drug interactions (cyp enzyme metabolism). including cyp3a4 |
|
|
Term
| zafiurlukast adverse effects |
|
Definition
| gi disturbacned and drug-drug interacitons - cyp3a4 |
|
|
Term
| montelukast adverse effects |
|
Definition
| no heaptotoxicity, does not itneract iwht cyp enzymes |
|
|
Term
|
Definition
| anti IGE therapy for asthma |
|
|
Term
| anti ge therapy moa for asthma |
|
Definition
| prevent inreaction with mast cells preventing activation |
|
|
Term
|
Definition
|
|
Term
| anti ige therapy benefits |
|
Definition
| lessens frequency and severity of attacks, while reudcing corticosteroid requirements. Reduced exacerbations requiring hospitilziations . howeverh ihgh costs |
|
|
Term
|
Definition
| because it is mouse, it may cause some anaphylaxis. |
|
|
